Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
PI3K inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
Taselisib
|
| gptkbp:CASNumber |
1282512-48-4
|
| gptkbp:chemicalFormula |
C23H24F3N5O2S
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Genentech
|
| https://www.w3.org/2000/01/rdf-schema#label |
GDC-0032
|
| gptkbp:investigatedBy |
gptkb:cancer
solid tumors |
| gptkbp:mechanismOfAction |
inhibits phosphoinositide 3-kinase
|
| gptkbp:target |
gptkb:PI3K_beta
gptkb:PI3K_gamma gptkb:PI3K_delta gptkb:PI3K_alpha |
| gptkbp:trialSponsor |
gptkb:Roche
|
| gptkbp:usedIn |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:taselisib
|
| gptkbp:bfsLayer |
6
|